CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also develops CAN106, an anti-C5 mAb for paroxysmal nocturnal hemoglobinuria; and CAN103, a recombinant human ERT for the treatment of gaucher disease. In addition, the company develops CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody for X-linked hypophosphatemia; CAN104, a recombinant human ERT GLA for fabry disease; CAN105, a bispecific antibody for the treatment of hemophilia A; and CAN204 to treat Duchenne muscular dystrophy. It has a license agreement with Mirum Pharmaceuticals, Inc. for the development, manufacture, and commercialization of Livmarli. CANbridge Pharmaceuticals Inc. was founded in 2012 and is headquartered in Suzhou, China.
Metrics to compare | 1228 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship1228PeersSector | |
---|---|---|---|---|
P/E Ratio | −0.9x | −52.3x | −0.5x | |
PEG Ratio | 0.05 | −0.12 | 0.00 | |
Price/Book | −0.8x | 6.1x | 2.6x | |
Price / LTM Sales | 4.4x | 26.3x | 3.2x | |
Upside (Analyst Target) | - | −10.4% | 42.0% | |
Fair Value Upside | Unlock | −16.0% | 6.6% | Unlock |